Recently, another study in colorectal cancer highlights the role of c-Met in mediating primary and secondary resistance to anti-EGFR therapies and encourages the use of c-Met inhibitors in patients displaying resistance as a result of c-Met amplification [17]. The gene discussed is EGFR; the disease is colorectal cancer.